MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-24-2026
Danaher Corporation General and Administrative Expenses 2011-2026 | DHR
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses Danaher Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 8.24 B | 7.76 B | 7.33 B | 7.12 B | 6.82 B | 6.9 B | 5.59 B | 6.47 B | 6.04 B | 5.61 B | 6.05 B | 5.7 B | 5.43 B | 5.18 B | 4.61 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 8.24 B | 4.61 B | 6.32 B |
Quarterly General and Administrative Expenses Danaher Corporation
| 2025-Q1 | 2024-Q4 | 2024-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.86 B | - | 1.81 B | - | - | 2.08 B | 2.09 B | - | 2.06 B | 1.97 B | 1.88 B | - | 1.8 B | 1.68 B | 1.46 B | - | 1.38 B | 1.39 B | 1.37 B | - | 1.56 B | 1.64 B | 1.6 B | - | 1.5 B | 1.52 B | 1.45 B | - | 1.35 B | 1.43 B | 1.33 B | - | 1.2 B | 1.4 B | 1.41 B | - | 1.3 B | 1.39 B | 1.35 B | - | 1.3 B | 1.34 B | 1.3 B | - | 1.25 B | 1.28 B | 1.24 B | - | 1.27 B | 1.09 B | 963 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.09 B | 963 M | 1.49 B |
General and Administrative Expenses of other stocks in the Diagnostics research industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Burning Rock Biotech Limited
BNR
|
490 M | $ 17.1 | 0.56 % | $ 181 M |  China |
 |
CareDx, Inc
CDNA
|
108 M | $ 21.5 | 3.32 % | $ 1.15 B |  USA |
 |
Centogene N.V.
CNTG
|
46.7 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Accelerate Diagnostics
AXDX
|
39.2 M | - | -61.36 % | $ 2.46 M | USA |
 |
Agilent Technologies
A
|
1.62 B | $ 114.52 | -0.86 % | $ 34.8 B | USA |
 |
Co-Diagnostics
CODX
|
9.06 M | $ 1.55 | - | $ 2.06 M | USA |
 |
Castle Biosciences
CSTL
|
200 M | $ 24.81 | 1.31 % | $ 689 M | USA |
|
Akumin
AKU
|
2.08 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Biocept
BIOC
|
16.1 M | - | -13.05 % | $ 7.29 M | USA |
 |
Aspira Women's Health
AWH
|
7.96 M | - | -6.19 % | $ 10.5 M | USA |
 |
Fulgent Genetics
FLGT
|
88.1 M | $ 14.13 | -6.98 % | $ 427 M | USA |
 |
ICON Public Limited Company
ICLR
|
585 M | $ 112.85 | -4.63 % | $ 9.31 B |  Irlanda |
 |
Chembio Diagnostics
CEMI
|
24.3 M | - | 0.22 % | $ 16.8 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
22.3 M | - | - | $ 562 M |  Britain |
 |
Check-Cap Ltd.
CHEK
|
9.46 M | - | - | $ 9.42 M |  Israel |
 |
Heska Corporation
HSKA
|
64.1 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
15.8 M | - | -20.0 % | $ 1.06 M | USA |
 |
Illumina
ILMN
|
1.09 B | $ 135.78 | 7.13 % | $ 21.6 B | USA |
 |
Lantheus Holdings
LNTH
|
275 M | $ 85.5 | 1.04 % | $ 5.77 B | USA |
 |
DermTech
DMTK
|
43.8 M | - | -11.32 % | $ 2.94 M | USA |
 |
Global Cord Blood Corporation
CO
|
187 M | - | - | $ 399 M | China |
 |
Fluidigm Corporation
FLDM
|
97.9 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
3.83 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
126 M | - | 0.12 % | $ 80.1 M | China |
 |
Myriad Genetics
MYGN
|
257 M | $ 4.8 | 1.05 % | $ 444 M | USA |
 |
NeoGenomics
NEO
|
273 M | $ 9.44 | 1.94 % | $ 1.21 B | USA |
 |
Medpace Holdings
MEDP
|
198 M | $ 417.54 | -0.27 % | $ 12 B | USA |
 |
National Research Corporation
NRC
|
54.8 M | $ 17.41 | 5.77 % | $ 390 M | USA |
 |
Charles River Laboratories International
CRL
|
743 M | $ 165.78 | -0.71 % | $ 8.22 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
453 M | - | - | $ 10.7 B | USA |
 |
Koninklijke Philips N.V.
PHG
|
599 M | $ 26.16 | -0.87 % | $ 20 B |  Niderland |
 |
Enzo Biochem
ENZ
|
21.7 M | - | -8.98 % | $ 14.8 K | USA |
 |
Exact Sciences Corporation
EXAS
|
889 M | - | - | $ 19.8 B | USA |
 |
Guardant Health
GH
|
211 M | $ 87.6 | 0.6 % | $ 11 B | USA |
 |
Personalis
PSNL
|
46.2 M | $ 5.78 | 4.71 % | $ 342 M | USA |
 |
Motus GI Holdings
MOTS
|
6.58 M | - | -34.28 % | $ 263 K | Israel |
 |
Interpace Biosciences
IDXG
|
9.48 M | $ 2.12 | 7.07 % | $ 9.38 M | USA |
 |
Senseonics Holdings
SENS
|
52.5 M | $ 5.1 | -22.84 % | $ 213 M | USA |
 |
Soleno Therapeutics
SLNO
|
132 M | $ 52.87 | 0.09 % | $ 2.69 B | USA |
 |
Thermo Fisher Scientific
TMO
|
8.73 B | $ 469.21 | -2.04 % | $ 177 B | USA |
 |
QIAGEN N.V.
QGEN
|
128 M | - | - | $ 10.6 B | Niderland |
 |
Twist Bioscience Corporation
TWST
|
247 M | $ 60.4 | 3.34 % | $ 3.61 B | USA |
 |
Biomerica
BMRA
|
2.98 M | $ 2.19 | 0.46 % | $ 5.03 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
2.22 B | $ 255.84 | -0.37 % | $ 21.3 B | USA |
 |
Celcuity
CELC
|
27.2 M | $ 125.65 | 3.54 % | $ 5.88 B | USA |
 |
Natera
NTRA
|
589 M | $ 207.28 | 0.54 % | $ 20.4 B | USA |
 |
Neogen Corporation
NEOG
|
218 M | $ 9.53 | 1.38 % | $ 2.07 B | USA |
 |
Invitae Corporation
NVTA
|
192 M | - | - | $ 21.2 M | USA |
 |
Waters Corporation
WAT
|
240 M | $ 307.12 | -0.68 % | $ 18.3 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
1.97 B | $ 192.67 | -0.79 % | $ 21.4 B | USA |